ArticleFrontiers in oncology2025
Nomogram based on the novel index LANR, composed of preoperative lymphocytes, albumin, and neutrophils, for predicting prognosis in patients with gastric cancer: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The prognostic value of lymphocyte-albumin-neutrophil ratio variability in patients with breast cancer undergoing radiotherapy.Frontiers in oncology · 2026Article
- Unveiling prognostic genes and regulatory mechanisms of stress granules in gastric cancers: an integrated analysis of bulk transcriptomics and single-cell RNA sequencing.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to explore the relationship between the novel index LANR, which is composed of preoperative lymphocytes, neutrophils, and albumin, and prognosis in patients with gastric cancer (GC), and to develop and visualize a new nomogram for predicting overall survival (OS) in GC patients. Methods: A total of 497 patients (346 in the training cohort and 151 in the validation cohort) with GC who underwent radical resection were retrospectively analyzed. The LANR was calculated as the lymphocyte×albumin/neutrophil. Collinearity diagnostic analysis was performed to assess the correlations between variables. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors for OS, which were then used to construct a nomogram model. The efficacy of the nomogram was subsequently evaluated in the validation cohort. Results: Multivariate Cox regression analysis showed that tumor size (Hazard ratio [HR]=1.653, P = 0.001), T stage (HR = 3.236, P<0.001), N stage (HR = 2.059, P<0.001), chemotherapy (HR = 1.508, P = 0.005), and LANR (HR = 0.586, P<0.001) were independent significant risk factors for OS in patients with GC. The independent prognostic performance of LANR is superior compared to NLR, PNI and PLR. In the training cohort, the area under the curve (AUC) of the nomograms for predicting 3-, 5- and 7-year OS were 0.768(95% CI = 0.718-0.819), 0.832(95% CI = 0.790-0.875) and 0.893(95% CI = 0.830-0.956), respectively. The AUC of the nomogram for predicting 3-, 5- and 7-year OS were 0.795(95% CI = 0.719-0.871), 0.823(95% CI = 0.756-0.890) and 0.833(95% CI = 0.735-0.931), respectively, in the validation cohort. Both in the training and validation cohorts, the calibration curves showed good consistency between the actual survival rates and the predicted values from the nomogram. The Decision curve analysis also indicated that the model has clinical utility. Conclusion: LANR is an independent prognostic factor for GC. The newly developed nomogram demonstrates high accuracy and potential clinical utility in predicting the OS in GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.